21 June 2018 - Nocdurna sublingual tablets dissolve rapidly and have specific dosing designed for men and women to deliver a low and effective dose of desmopressin.

The U.S. FDA granted Ferring Pharmaceuticals approval to market Nocdurna, the first sublingual tablet for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void. The formulation of the sublingual tablet and sex-specific dosing was demonstrated to be effective in reducing nighttime trips to the bathroom in adults 18 years and older.

The FDA approval of Nocdurna is based on three double-blind placebo-controlled, multi-center, randomised trials and one open-label extension trial of up to three years in patients 18 years and older.

Read Ferring Pharmaceuticals press release